Geinitz H, Zimmermann F B, Stoll P, Thamm R, Kaffenberger W, Ansorg K, Keller M, Busch R, van Beuningen D, Molls M
Klinik und Poliklinik für Strahlentherapie und Radiologische Onkologie, Technische Universität München, München, Germany.
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):691-8. doi: 10.1016/s0360-3016(01)01657-1.
To assess the level of fatigue during the course of adjuvant radiotherapy (RT) of breast cancer patients and its relation to anxiety, depression, serum cytokines, and blood count levels.
Forty-one patients who received adjuvant RT after breast-conserving surgery were prospectively studied. All patients underwent RT without concomitant chemotherapy. Patients rated their fatigue with two standardized self-assessment instruments, the Fatigue Assessment Questionnaire and a visual analog scale on fatigue intensity, before RT, during weeks 1-5 of RT, and 2 months after RT completion. In addition, the anxiety and depression levels were assessed with the Hospital Anxiety and Depression Scale. A differential blood cell count and the serum levels of the cytokines interleukin (IL)-1beta, IL-6, and tumor necrosis factor-alpha were determined in parallel to the fatigue assessments.
Fatigue intensity as assessed with the visual analog scale increased (p <0.001) until treatment week 4 and remained elevated until week 5. Two months after RT, the values had fallen to the pretreatment levels. Fatigue measured with the Fatigue Assessment Questionnaire did not increase significantly during treatment, but the subscores on physical (p = 0.035) and cognitive (p = 0.015) fatigue were elevated during treatment weeks 4 and 5. Affective fatigue did not change significantly. Anxiety, as rated with the Hospital Anxiety and Depression Scale, declined during RT (p = 0.002), but the Hospital Anxiety and Depression Scale depression score did not change significantly. IL-1beta, IL-6, and tumor necrosis factor-alpha levels did not change during therapy and did not correlate with fatigue. Peripheral blood cell levels declined significantly during therapy and were still low 2 months after treatment. Until treatment week 5, lymphocytes were reduced to almost 50% of their initial values. Hemoglobin levels did not correlate with fatigue.
We observed an increase in fatigue during adjuvant RT of patients with breast cancer. Fatigue returned to pretreatment levels 2 months after treatment. No evidence was found that anxiety, depression, serum levels of IL-1beta, IL-6, tumor necrosis factor-alpha, or declining hemoglobin levels were responsible for the treatment-induced fatigue.
评估乳腺癌患者辅助放疗(RT)过程中的疲劳程度及其与焦虑、抑郁、血清细胞因子和血细胞计数水平的关系。
对41例保乳手术后接受辅助放疗的患者进行前瞻性研究。所有患者均接受放疗,未同时进行化疗。患者在放疗前、放疗第1 - 5周期间以及放疗结束后2个月,使用两种标准化的自我评估工具,即疲劳评估问卷和疲劳强度视觉模拟量表对疲劳程度进行评分。此外,使用医院焦虑抑郁量表评估焦虑和抑郁水平。在进行疲劳评估的同时,测定血细胞分类计数以及细胞因子白细胞介素(IL)-1β、IL-6和肿瘤坏死因子-α的血清水平。
通过视觉模拟量表评估的疲劳强度在治疗第4周前升高(p <0.001),并持续升高至第5周。放疗后2个月,该值降至治疗前水平。使用疲劳评估问卷测得的疲劳程度在治疗期间未显著增加,但在治疗第4周和第5周,身体(p = 0.035)和认知(p = 0.015)疲劳的子评分升高。情感疲劳无显著变化。根据医院焦虑抑郁量表评定,放疗期间焦虑程度下降(p = 0.002),但医院焦虑抑郁量表的抑郁评分无显著变化。治疗期间IL-1β、IL-6和肿瘤坏死因子-α水平无变化,且与疲劳无关。治疗期间外周血细胞水平显著下降,治疗后2个月仍较低。直至治疗第5周,淋巴细胞减少至初始值的近50%。血红蛋白水平与疲劳无关。
我们观察到乳腺癌患者辅助放疗期间疲劳程度增加。治疗后2个月疲劳程度恢复至治疗前水平。未发现证据表明焦虑、抑郁、IL-1β、IL-6、肿瘤坏死因子-α的血清水平或血红蛋白水平下降是治疗引起疲劳的原因。